SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Neurocrine Biosciences (NBIX)
An SI Board Since July 1996
Posts SubjectMarks Bans Symbol
1834 74 0 NBIX
Emcee:  Billy Dunn Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1584CFO just reported a margin call. Sad.scaram(o)uche-5/18/2006
1583George, FDA did not have to pass final decision on XR formulation by May 15. PDMiljenko Zuanic-5/18/2006
1582Rick, Hurry answered your questions about potency. Than again, if Indiplon is 1Miljenko Zuanic-5/18/2006
1581Closed out old position and went a little long this morning. I'm just lookikenhott-5/17/2006
1580Yeah - I think it was a conference call just to say that they had a conference cFiloF-5/17/2006
1579chuckle. true true true. (eom)mopgcw-5/17/2006
1578Agreed, although one has to wonder what the purpose of the CC was. Apart from stIcebrg-5/17/2006
1577I agree. I was not as dismayed as some at the lack of a q&a on the cc; it wmopgcw-5/17/2006
1576No one knows the answer for sure. Just a matter of who has a better crystal bakenhott-5/17/2006
1575Sonata goes generic Dec 2008.kenhott-5/17/2006
1574Lyons non-conference call: "The company is meeting with its partner Pfizer quidditch-5/17/2006
1573From kg q1 report.. Net sales of Sonata® (zaleplon) totaled $21 million durkrw-5/17/2006
1572Here is another article: biotechstockblog.com JonRobohogs-5/17/2006
1571Some comments from BioWorld bioworld.comIcebrg-5/17/2006
1570ooops, forgot to say thanks when I posted the abstract. thanks! :-)scaram(o)uche-5/17/2006
1569<i> FDA said clearly that at this time XR formulation is non-approvable pemopgcw-5/17/2006
1568smartmoney: Slumber Party Pooper By Will Swarts Published: May 16, 2006 The mopgcw-5/17/2006
1567J Pharmacol Exp Ther. 2006 Apr;317(1):369-77. Epub 2006 Jan 6. Indiplon is a scaram(o)uche-5/17/2006
1566MFool: The FDA Tries to Put Neurocrine to Sleep By Stephen D. Simpson, CFA (TMFWmopgcw-5/17/2006
1565Indiplon IR is more potent than Sonata/zaleplon: One old estimate I saw was 20-NeuroInvestment-5/17/2006
1564That 2003 post-Pfizer share issue turns out to have been a very good idea after Icebrg-5/17/2006
1563>> Unfortunately, old times are gone and, in general, it is harder to gainscaram(o)uche-5/17/2006
1562Hi Rick and others. Indiplon without extended formulation (XR) may be only bettMiljenko Zuanic-5/17/2006
1561Hope you're correct, that the FDA says "oops, wrong letter!" tomorscaram(o)uche-5/16/2006
1560Thanks (as usual) George. eomfred hayes-5/16/2006
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News